← All trials
NCT04994106
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 27, 2021
- Primary completion
- Mar 14, 2022
- Completion date
- Mar 14, 2022
- First posted
- Aug 6, 2021
- Last posted
- Nov 10, 2021
- Enrollment
- 128
- Arms / groups
- 17 / —
- Source
- AACT · ingestion pipeline
Sponsors
- AstraZenecaLead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.